February 27, 2017 – Watchung, NJ

Woodland International Research Group (WIRG) a subsidiary of Evolution Research Group, LLC (ERG), recently opened its new purpose-built, 16-bed CRU designed specifically for child and adolescent inpatient trials in special populations including those suffering from CNS disorders and diseases in other therapeutic areas. The facility features bedside gaming, an indoor gymnasium, air hockey, crafts and other activities as well as a secure outdoor area with fresh air space. Importantly, the unit’s patient retention program includes education and tutoring for school-aged study participants.

This custom-built facility was designed for the comfort of patients and family with two beds per room, which allows caregivers to stay overnight.  It is also equipped with separate exam and procedure rooms. The staff consists of a board-certified child and adolescent psychiatrist, a board-certified family practitioner also boarded in pain and addiction, RNs, LPNs, PCTs, nutritionists, CRCs, neuropsychiatric raters, phlebotomists, as well as regulatory, QC and ACLS certified staff. Recent pediatric Phase I/Inpatient studies performed at WIRG included schizophrenia, bipolar disorder, ADHD, depression and GERD.

The unit is also being utilized for adult and elderly Phase 1-2a inpatient trials, sleep disorder trials, and more complex studies with smaller cohorts, required serial PK draws, PSG, and other specialized procedures allowing separation from the adult psychiatric populations on the larger 40-bed main unit.

President and CEO, Ms. Lori Wright is enthusiastic about the new offering stating, “Studies in pediatric populations have become increasingly demanded by the industry, following changes in FDA guidance.  Expanding capabilities demonstrates our ability and flexibility to adapt to the ever-changing needs of our clients.  While studies in infants, children and adolescents come with a unique set of demands and concerns, we are experienced in working with these subjects and their families.” Woodland International Research Group is one of 6 Portfolio companies owned and managed by ERG.

ERG will be showcasing the new pediatric unit along with its other unique early development services at the 2017 American Society for Clinical Pharmacology and Therapeutics Annual Meeting being held March 15-18th, 2017, in Washington, D.C.  Visit ERG at Booth #50 to learn more or visit www.joinaresearchstudy.com.

About Evolution Research Group

Evolution Research Group represents Thievon-Wright Consulting Group and an elite 16-member network of owned and affiliate clinical research sites focused on conducting simple and highly complex trials in psychiatric and neurologic disorders, non-CNS indications, and early phase drug development.  Our network is comprised of 18 research facilities including 11 Clinical Pharmacology/Clinical Research/Pediatric and Adolescent Units, providing access to over 400 beds.  Thievon-Wright Consulting Group (TWCG) offers consulting services to pharmaceutical and CRO clients, including access to key opinion leaders in Schizophrenia, Pain, Alzheimer’s disease, Sleep Disorders, Depression, Hepatic/Renal Impairment, and Clinical Pharmacology.  In addition, TWCG also offers general consulting in study design, protocol review and budget planning, vendor resources, study feasibility and site recommendations. The Evolution Research Group network of Portfolio and Affiliate Sites focuses in specialized populations and normal healthy volunteers.